Chorioamnionitis (ChA) modifies CX3CL1 (fractalkine) production by human amniotic epithelial cells (HAEC) under normoxic and hypoxic conditions

Journal of Inflammation (United Kingdom)

Volumn 11, Issue 1, 2014, Pages

  Szukiewicz, Dariusz ^a   Kochanowski, Jan ^a   Mittal, Tarun Kumar ^a   Pyzlak, Michal ^a   Szewczyk, Grzegorz ^a   Cendrowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Chorioamnionitis; CX3CL1; Fractalkine; Human amniotic epithelial cells; Hypoxia

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY;

AMNION CELL; ARTICLE; CELL CULTURE; CELL HYPOXIA; CHORIOAMNIONITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN AMNIOTIC EPITHELIAL CELL; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

EID: 84988497604     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-11-12     Document Type: Article

References (62)

1. Steinke JW, Borish L: 3. Cytokines and chemokines. J Allergy Clin Immunol 2006, 117(Suppl 2 Mini-Primer):441-445.
2. Raman D, Sobolik-Delmaire T, Richmond A: Chemokines in health and disease. Exp Cell Res 2011, 317:575-589.
3. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
4. Kim KW, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G, Ludwig A, Lira SA, Jung S: In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 2011, 118:e156-e167.
5. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
6. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, GutierrezRamos JC, Gearing D: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387:611-617.
7. Erratum in: Nature 1997, 389:100.
8. Yoshikawa M, Nakajima T, Matsumoto K, Okada N, Tsukidate T, Iida M, Otori N, Haruna S, Moriyama H, Imai T, Saito H: TNF-alpha and IL-4 regulate expression of fractalkine (CX3CL1) as a membrane-anchored proadhesive protein and soluble chemotactic peptide on human fibroblasts. FEBS Lett 2004, 561:105-110.
9. Schwarz N, Pruessmeyer J, Hess FM, Dreymueller D, Pantaler E, Koelsch A, Windoffer R, Voss M, Sarabi A, Weber C, Sechi AS, Uhlig S, Ludwig A: Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cell Mol Life Sci 2010, 67:4233-4248.
10. Imaizumi T, Yoshida H, Satoh K: Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004, 11:15-21.
11. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
12. Doggrell SA: CX3CR1 as a target for airways inflammation. Expert Opin Ther Targets 2011, 15:1139-1142.
13. Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, Chavez SL, Romero R, Mor G: Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol 2007, 57:55-66.
14. Red-Horse K, Drake PM, Fisher SJ: Human pregnancy: the role of chemokine networks at the fetal-maternal interface. Expert Rev Mol Med 2004, 6:1-14.
15. Dimitriadis E, Nie G, Hannan NJ, Paiva P, Salamonsen LA: Local regulation of implantation at the human fetal-maternal interface. Int J Dev Biol 2010, 54:313-322.
16. Yip L, McCluskey J, Sinclair R: Immunological aspects of pregnancy. Clin Dermatol 2006, 24:84-87.
17. Hunt JS: Stranger in a strange land. Immunol Rev 2006, 213:36-47.
18. Kraus TA, Sperling RS, Engel SM, Lo Y, Kellerman L, Singh T, Loubeau M, Ge Y, Garrido JL, Rodríguez-García M, Moran TM: Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am J Reprod Immunol 2010, 64:411-426.
19. Shimoya K, Zhang Q, Tenma K, Ota Y, Hashimoto K, Shizusawa Y, Kimura T, Koyama M, Murata Y: Fractalkine (FRK) levels in amniotic fluid and its production during pregnancy. Mol Hum Reprod 2003, 9:97-101.
20. Bowen JM, Chamley L, Mitchell MD, Keelan JA: Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 2002, 23:239-256.
21. Hannan NJ, Jones RL, White CA, Salamonsen LA: The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface. Biol Reprod 2006, 74:896-904.
22. Hannan NJ, Salamonsen LA: CX3CL1 and CCL14 regulate extracellular matrix and adhesion molecules in the trophoblast: potential roles in human embryo implantation. Biol Reprod 2008, 79:58-65.
23. Chu L, Li X, Yu W, Qian T, Qi H, Huang L, Xu Y: Expression of fractalkine (CX3CL1) and its receptor in endotoxin-induced uveitis. Ophthalmic Res 2009, 42:160-166.
24. Park J, Song KH, Ha H: Lipopolysaccharide increases monocyte binding to mesangial cells through fractalkine and its receptor. Transplant Proc 2012, 44:1029-1031.
25. Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A: NFκB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 2012, 69:1319-1329.
26. Yamashita K, Imaizumi T, Hatakeyama M, Tamo W, Kimura D, Kumagai M, Yoshida H, Satoh K: Effect of hypoxia on the expression of fractalkine in human endothelial cells. Tohoku J Exp Med 2003, 200:187-194.
27. van Meurs M, Wulfert FM, Jongman RM, Schipper M, Houwertjes MC, Vaneker M, Scheffer GJ, Teppema LJ, Aarts LP, Heeringa P, Zijlstra JG, Molema G: Hemorrhagic shock-induced endothelial cell activation in a spontaneous breathing and a mechanical ventilation hemorrhagic shock model is induced by a proinflammatory response and not by hypoxia. Anesthesiology 2011, 115:474-482.
28. Dénes A, Ferenczi S, Halász J, Környei Z, Kovács KJ: Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008, 28:1707-1721.
29. Kataoka T: Chemical biology of inflammatory cytokine signaling. J Antibiot (Tokyo) 2009, 62:655-667.
30. Miyazaki K, Furuhashi M, Matsuo K, Minami K, Yoshida K, Kuno N, Ishikawa K: Impact of subclinical chorioamnionitis on maternal and neonatal outcomes. Acta Obstet Gynecol Scand 2007, 86:191-197.
31. Bersani I, Thomas W, Speer CP: Chorioamnionitis - the good or the evil for neonatal outcome? J Matern Fetal Neonatal Med 2012, 25(Suppl 1):12-16.
32. Redline RW: Inflammatory response in acute chorioamnionitis. Semin Fetal Neonatal Med 2012, 17:20-25.
33. Szukiewicz D, Szewczyk G, Pyzlak M, Klimkiewicz J, Maslinska D: Increased production of beta-defensin 3 (hBD-3) by human amniotic epithelial cells (HAEC) after activation of toll-like receptor 4 in chorioamnionitis. Inflamm Res 2008, 57(Suppl 1):1-2.
34. Okita JR, Sagawa N, Casey ML, Snyder JM: A comparison of human amnion tissue and amnion cells in primary culture by morphological and biochemical criteria. In Vitro 1983, 19:117-126.
35. Szukiewicz D, Gujski M, Maslinska D, Szewczyk G, Bachanek M, Maslinski S: Mast cell-derived VEGF and VEGF receptor type 1,2 and 3 expression in human term trophoblast culture - influence of hypoxia. Inflamm Res 2005, 54(Suppl 1):82-83.
36. Huppertz B, Abe E, Murthi P, Nagamatsu T, Szukiewicz D, Salafia C: Placental angiogenesis, maternal and fetal vessels - a workshop report. Placenta 2007, 28(Suppl A):94-96.
37. Cartwright JE, Keogh RJ, Tissot van Patot MC: Hypoxia and placental remodeling. Adv Exp Med Biol 2007, 618:113-126.
38. Murphy VE, Smith R, Giles WB, Clifton VL: Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr Rev 2006, 27:141-169.
39. Mackenzie IZ: Induction of labour at the start of the new millennium. Reproduction 2006, 131:989-998.
40. Pavan B, Paganetto G, Dalpiaz A, Biondi C, Lunghi L: Estrogen metabolites in the release of inflammatory mediators from human amnion-derived cells. Life Sci 2011, 88:551-558.
41. Jabbour HN, Sales KJ, Catalano RD, Norman JE: Inflammatory pathways in female reproductive health and disease. Reproduction 2009, 138:903-919
42. Yang Z, Kong B, Mosser DM, Zhang X: TLRs, macrophages, and NK cells: our understandings of their functions in uterus and ovary. Int Immunopharmacol 2011,11:1442-1450.
43. Rademacher TW, Gumaa K, Scioscia M: Preeclampsia, insulin signalling and immunological dysfunction: a fetal, maternal orplacental disorder? J Reprod Immunol 2007, 76:78-84.
44. Weiss G, Goldsmith LT, Taylor RN, Bellet D, Taylor HS: Inflammation in reproductive disorders. Reprod Sci 2009, 16:216-229
45. Wu HC, Shen CM, Wu YY, Yuh YS, Kua KE: Subclinical histologic chorioamnionitis and related clinical and laboratory parameters in preterm deliveries. Pediatr Neonatol 2009, 50:217-221
46. Coussons-Read ME, Lobel M, Carey JC, Kreither MO, DAnna K, Argys L, Ross RG, Brandt C, Cole S: The occurrence of preterm delivery is linked to pregnancy-specific distress and elevated inflammatory markers across gestation. Brain Behav Immun 2012, 26:650-659.
47. Lim S, MacIntyre DA, Lee YS, Khanjani S, Terzidou V, Teoh TG, Bennett PR: Nuclear factor kappa B activation occurs in the amnion prior to labour onset and modulates the expression of numerous labour associated genes. PLoS One 2012, 7:e34707.
48. Zaga-Clavellina V, Martha RV, Flores-Espinosa P: In vitro secretion profile of pro-inflammatory cytokines IL-1B, TNF-a, IL-6, and ofhuman beta-defensins (HBD)-1, HBD-2, and HBD-3 from human chorioamniotic membranes after selective stimulation with Gardnerella vaginalis. Am J Reprod Immunol 2012, 67:34-43
49. Hauguel-de Mouzon S, Guerre-Millo M: The placenta cytokine network and inflammatory signals. Placenta 2006, 27:794-798
50. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, Matsumiya T, Tanji K, Shibata T, Tamo W, Kumagai M, Satoh K: Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett 2001, 303:132-136
51. Isozaki T, Otsuka K, Sato M, Takahashi R, Wakabayashi K, Yajima N, Miwa Y, Kasama T: Synergistic induction of CX3CL1 by interleukin-1(3 and interferon-y in human lung fibroblasts: involvement of signal transducer and activator of transcription 1 signaling pathways. Transl Res 2011, 157:64-70.
52. Melican K, Boekel J, Månsson LE, Sandoval RM, Tanner GA, Källskog O, Palm F, Molitoris BA, Richter-Dahlfors A: Bacterial infection-mediated mucosal signaling induces local renal ischaemia as a defense against sepsis. Cell Microbiol 2008, 10:1987-1998.
53. Petcu EB, Kocher T, Kuhr A, Buga AM, Klöting I, Herndon JG, Kessler C, Popa-Wagner A: Mild systemic inflammation has a neuroprotective effect after stroke in rats. Curr Neurovasc Res 2008, 5:214-223.
54. Ahn SY, Cho CH, Park KG, Lee HJ, Lee S, Park SK, Lee IK, Koh GY: Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 2004, 164:1663-1672
55. Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K: Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. J Immunol 2010,184:4205-4214.
56. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, Melby PC: Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003, 373:547-558.
57. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S: CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009, 113:963-972.
58. Huang LY, Chen P, Xu LX, Zhou YF, Zhang YP, Yuan YZ: Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model. Inflammation 2012, 35:1023-1030.
59. Todorova D, Sabatier F, Doria E, Lyonnet L, Vacher-Coponat H, Robert S, Despoix N, Legris T, Moal V, Loundou A, Morange S, Berland Y, George FD, Burtey S, Paul P: Fractalkine expression induces endothelial progenitor cell lysis by natural killer cells. PLoS One 2011, 6:e26663.
60. Niessner A, Marculescu R, Haschemi A, Endler G, Zorn G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K: Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome: a possible implication of fractalkine in inflammatory activation. Thromb Haemost 2005, 93:949-954.
61. Lavergne E, Labreuche J, Daoudi M, Debré P, Cambien F, Deterre P, Amarenco P, Combadière C: GENIC Investigators. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:847-853.
62. Apostolakis S, Amanatidou V, Papadakis EG, Spandidos DA: Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009, 207:8-15.